DexCom, Inc. (DXCM)
Here's Why DexCom (DXCM) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cinctive Capital Management LP Takes $4.45 Million Position in DexCom, Inc. $DXCM
Cinctive Capital Management LP purchased a new stake in shares of DexCom, Inc. (NASDAQ: DXCM) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 66,148 shares of the medical device company's stock, valued at approximately $4,451,000. A number of other institutional investors have also added to
Bamco Inc. NY Reduces Stock Position in DexCom, Inc. $DXCM
Bamco Inc. NY decreased its holdings in DexCom, Inc. (NASDAQ: DXCM) by 18.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 272,500 shares of the medical device company's stock after selling 60,000 shares during the period. Bamco Inc. NY
Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why DexCom (DXCM) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DexCom: Gaining Favor, With Useful Tailwinds To Support It Even Further
Dexcom has been outperforming its peers since our last coverage in December. I expect further progress this year, as the company's long-suffering gross margin profile is set to reverse course over the next fewyears with +200bps of improvements expected this year alone. DXCM's earnings multiple is pricier than other medical equipment peers, but if the degree of medium term earnings growth is taken into consideration, its valuations look cheap.
DexCom, Inc. (DXCM) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
DexCom, Inc. (DXCM) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth
DXCM beats Q4 EPS estimates, posts 13% revenue growth and reiterates 2026 guidance as G7 15 Day rollout and margin gains drive momentum.
DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript
DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript
DexCom (DXCM) Q4 Earnings and Revenues Top Estimates
DexCom (DXCM) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.45 per share a year ago.
